Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival

CONCLUSION: The administration of MTAs in patients with intermediate-stage HCC contributes to the prevention of stage progression and prolongs OS.PMID:34518483 | DOI:10.1159/000518612
Source: Oncology - Category: Cancer & Oncology Authors: Source Type: research